Successful Setting of Reimbursement Standards for the Treatment of Multiple Myeloma with "Inrebic Capsules"
The reimbursement standards have been set for the treatment of multiple myeloma with Inrebic capsules (fedratinib, manufactured by Korea BMS Pharmaceutical), paving the way for coverage by health insurance.
Additionally, the reimbursement standards have been expanded for the ovarian cancer treatment drug, ZEJULA capsules (niraparib, manufactured by Korea Daiichi Sankyo).
If these drugs pass the evaluation of the Pharmaceutical Benefit Evaluation Committee and the drug pricing negotiation with the National Health Insurance Corporation, they will be added to the final reimbursement list.
The Pharmaceutical Benefit Evaluation Committee announced that it reviewed and approved the validity of the reimbursement standards for Inrebic capsules at the first Cancer Disease Review Committee meeting held on January 1, 2023.
Inrebic capsules are effective for treating the spleen or symptoms associated with the following diseases in adult patients who have received previous treatment with ruxolitinib: primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
Moreover, ZEJULA capsules have been deemed valid for reimbursement standards for the maintenance monotherapy of adult patients with ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who have responded (partial or complete response) to first-line platinum-based chemotherapy and have a germline BRCA mutation.
On the other hand, the reimbursement standards for Tabrecta tablets and tepmetko tablets, treatments for non-small cell lung cancer with MET exon 14 skipping alterations, have failed.
The Cancer Disease Review Committee has also opposed the establishment of reimbursement standards for Portrazza injection (necitumumab, manufactured by Kyowa Kirin Korea) for the treatment of squamous cell carcinoma or syndrome in adult patients.